HCM’s GEO: Earned Media as AI Discoverability Infrastructure for HUTCHMED (China)

AI visibility as medical communications infrastructure

HCM, a public relations firm, expands its Generative Engine Optimization (GEO) services to help companies in regulated sectors such as biopharma secure visibility in an AI-first discovery environment. The firm points to data showing more than 800 million people use AI for answers weekly and that 94% of links cited by AI come from non-paid media, arguing that earned coverage now acts as a primary source of credibility for large language models. For drug developers like HUTCHMED (China), which rely on accurate interpretation of clinical data and safety profiles, the approach reframes media relations as infrastructure for machine-mediated discovery rather than a publicity add-on.

HCM’s GEO methodology centers on positioning high-credibility earned coverage as the foundation for LLM-driven discoverability, then layering LLM-optimized explainers and multi-channel amplification. In practice the firm fuses traditional media relations, data-driven story ideation and prompt engineering to produce explainers and syndicated distribution that feed models such as ChatGPT, Claude and Gemini. For biopharma companies, this chain matters because AI systems increasingly surface summaries and links that inform patient decisions, clinician awareness and regulatory scrutiny; trusted, widely distributed narratives reduce the risk of misrepresentation when clinical findings are interpreted by automated systems.

The agency presents early client outcomes as proof points for conversion and reputation management that are relevant to HUTCHMED’s sector. Examples include a 400% traffic uplift after educational content reframed industry safety concerns following a major study, and improved placement in AI-generated recommendations after targeted syndication across business and lifestyle outlets. HCM’s founder argues that AI amplifies the value of earned stories rather than replacing public relations, and that without clear, trusted narratives models lack meaningful reference points — a consideration that affects how pharmaceutical companies communicate trial results, safety signals and therapeutic positioning.

Broader implications for biotech communications

HCM pairs media relations with LLM prompt engineering and syndication tactics to compound authority signals and secure conversion-driving links and top-ranking placements. For HUTCHMED and peers, adopting similar workflows could strengthen patient-facing explainers, investor and clinician outreach, and crisis management in an environment where automated summaries often set first impressions.

Market positioning and uptake

The firm positions GEO as a strategic investment for 2026 visibility, arguing that earned media becomes essential infrastructure for brands seeking sustained relevance across AI platforms. Biopharma companies evaluating their external communications are increasingly weighing how earned credibility and AI-ready content combine to influence discoverability and trust.